Stock ALDER BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Alder BioPharmaceuticals, Inc.

Equities

US0143391052

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alder BioPharmaceuticals, Inc. Announces Board Changes
CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P Biotechnology Select Industry Index
CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P Global BMI Index
CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P TMI Index
CI
H. Lundbeck A/S completed the acquisition of Alder BioPharmaceuticals, Inc..
CI
Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC
GL
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
GL
Alder BioPharmaceuticals, Inc. Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
CI
WeissLaw LLP Investigates Alder Biopharmaceuticals, Inc.
PR
H Lundbeck : Lundbeck buys Alder in $2 billion migraine treatment move
RE
Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash
GL
H. Lundbeck A/S signed a Letter of Intent to acquire Alder BioPharmaceuticals, Inc. for $1.5 billion.
CI
Transcript : Alder BioPharmaceuticals, Inc. Presents at Morgan Stanley 17th Annual Global Healthcare Conference, Sep-10-2019 02:55 PM
Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society
GL
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences
GL
Transcript : Alder BioPharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019
Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results
GL
Alder Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
CI
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Alder BioPharmaceuticals, Inc.